CFS Investment Advisory Services’s Zimmer Biomet ZBH Stock Holding History

CFS Investment Advisory Services’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23,733	Closed	–	–	284
2022 Q3	$0	Buy	+23,733	New	+$2.6M	﹤0.01%	372
2022 Q2	–	Sell	-20,208	Closed	–	–	550
2022 Q1	$0	Buy	+20,208	New	+$2.44M	﹤0.01%	561

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CFS Investment Advisory Services's ZBH Position: Q4 2022 in Review

CFS Investment Advisory Services sold out of Zimmer Biomet (ZBH) in Q4 2022, closing a stake of 23,733 shares.

CFS Investment Advisory Services first reported a position in ZBH in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 977 funds tracked by Wall St. Rank hold ZBH as of Q4 2022.

CFS Investment Advisory Services reported no remaining Zimmer Biomet position as of Q4 2022 after selling out during the quarter.
CFS Investment Advisory Services sold 23,733 Zimmer Biomet shares in Q4 2022.
CFS Investment Advisory Services first reported a position in Zimmer Biomet in Q1 2022 and held it in 2 quarters.
CFS Investment Advisory Services's Zimmer Biomet position peaked at $0 in Q3 2022.
977 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2022.

Based on CFS Investment Advisory Services's 13F filing for Q4 2022, filed 13 Feb 2023.